Kistner RW

The use of the various new progestins in the treatment of endometrio sis is reported. Data from at least 6 separate investigators indicate an improvement rate of between 75% and 85%. In 1958 Kistner reported results in 12 patients using com…

Methods of administration side effects and pharmacology of 4 proges tins employed in treating endometriosis were presented. 17-alpha-hydrox yprogesterone caproate (Delalutin) 17-alpha-ethinyl-17-hydroxy-5-10-est ren-3-one (norethynodrel) wi…

CA-125 is a high-molecular-weight glycoprotein that is expressed on the cell surface of some derivatives of embryonic coelomic epithelium. Based on results of an immunoradiometric assay developed to detect CA-125 in peripheral blood, 82% of…

A prospective study to evaluate the efficacy of danazol in the treatment of endometriosis was initiated in 1976. One hundred patients with endometriosis, as demonstrated by laparoscopy, were entered into the study. The mean length of patien…

A 20-year-old single woman suffers from severe dysmenorrhea, unresponsive to analgesic medication. Findings for gynecological examination were normal. Her mother died of mammary cancer at the age of 47. This cancer was diagnosed at age 42 w…

This paper outlines methods of therapy utilizing newer combinations of estrogens and progestins. The specific agent and length of treatment depends on the extent of disease, severity of symptoms, presence of infertility and response to pseu…

From the Department of Obstetrics and Gynecology, Harvard Medical School, Boston, and the Free Hospital for Women, Brookline, Massachusetts

Progestational agents are being used with increasing frequency in disorders such as endometriosis, severe dysmenorrhea, disseminated endometrial carcinoma, mastodynia, etc. It is important to know their structure, laboratory evaluation and …